PCSK9促进Ⅰ型心肌梗死的研究进展  

Research progress of PCSK9 promoting type I myocardial infarction

作　　者：吴万泰 李上海 张兴斌 梁伟钧 Wu Wantai;Li Shanghai;Zhang Xingbin;Liang Weijun(Department of Cardiovascular Medicine,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属医院心血管内科,湛江524000

出　　处：《中国综合临床》2024年第5期390-394,共5页Clinical Medicine of China

基　　金：广东省湛江市科技项目(2022A01187)。

摘　　要：前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(recombinant proprotein convertase subtilisin/kexin type 9,PCSK9)作为胆固醇稳态的关键调节因子,可诱导降解低密度脂蛋白受体(low density lipoprotein receptor,LDLR)来调节循环低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平,抑制PCSK9作用后可降低血脂正常者发生I型心肌梗死的风险。I型心肌梗死的根源在于自发形成的冠状动脉粥样血栓引发的心肌坏死,而在这个过程中,PCSK9所起的调节血脂作用已超出了原有的范畴。临床上,探索这一领域可能会增进医师对PCSK9在I型心肌梗死中的作用的理解,为I型心肌梗死的二级预防和治疗提供新思路。As a key regulator of cholesterol homeostasis,the pre protein converting enzyme Bacillus subtilisin/kexin type 9(PCSK9)can induce the degradation of LDL receptors(LDLR)to regulate circulating low-density lipoprotein cholesterol(LDL-C)levels.Inhibiting the action of PCSK9 can reduce the risk of type I myocardial infarction in individuals with normal blood lipids.The root cause of type I myocardial infarction is myocardial necrosis caused by spontaneous coronary atherosclerotic thrombosis,and in this process,the role of PCSK9 in regulating blood lipids has gone beyond the original scope.Clinically,exploring this area may enhance physicians'understanding of the role of PCSK9 in type I myocardial infarction and provide new ideas for secondary prevention and treatment of type I myocardial infarction.

关 键 词：Ⅰ型心肌梗死 前蛋白转化酶枯草杆菌蛋白酶/kexin 9型 冠状动脉斑块 血栓形成 低密度脂蛋白胆固醇 

分 类 号：R542.22[医药卫生—心血管疾病]